1. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Status of GI Allergan-abbvie merger

Discussion in 'Allergan' started by anonymous, Jul 5, 2019 at 1:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    There is an overlap product with GI in Allergan and Abbvie. Will they sell off Zenpep before the acquisition and let people go then? When and would it be Zenpep or creon folks?
     
  2. anonymous

    anonymous Guest

    Abbvie people stay and Allergan people are fired. That’s all you need to know
     
  3. anonymous

    anonymous Guest

    We (Allergan GI) are gonna be hit hard if not obliterated. Any DM with Allergan is most likely fired and primary care will take a big hit too. Those are all obvious though
     
  4. anonymous

    anonymous Guest

    Not sure why everyone assumes the GI team is done just because of zenpep. Linzess is the GI flagship product and still remains. GI is supposed to launch ubrogepant. Just depends on the direction they take. We'll just have to wait and see.
     
  5. anonymous

    anonymous Guest


    Allergan has to divest Zenpep BEFORE the deal closes.

    That leaves Linzess, which Allergan only has partial ownership, and Viberzi which is a total dog that has barely been promoted.
     
  6. anonymous

    anonymous Guest

    Hahaha just like all the other Abbott /abbvie deals abbvie throws their own to the wolves
     
  7. anonymous

    anonymous Guest

    Not sure what will happen this time but I can tell you from the KOS experience...It was a bloodbath for Abbott Reps.
     
  8. anonymous

    anonymous Guest

    Correct me if I’m wrong but doesnt Abbvie already have 3 different GI teams: hep C, humira for Crohns/colitis, and the creon team in GI, PC, and CF? They've been in GI for years and those reps have longevity. Not sure what that means for either company.
     
  9. anonymous

    anonymous Guest

    It means they don’t need Allergan GI twos not managers lmao.

    Allergan only co-promotes LZ which we can do easily in their place. And anybody can promote Viberzi that’s already at Abbie even though it’s a loser drug that nobody wants to talk about
     
  10. anonymous

    anonymous Guest

    “Combined SG&A for the two companies was $11.7B in 2018. An $800M reduction represents less than 7% of the total, which is again a fairly small amount which should be easily achievable. If anything, we should expect a higher amount of synergies here.”
    Most likely from Allergan GI and PCR. On the call to investors, Rick G made it seem pretty clear Abbvie employees will be kept as much as possible. Allergan offers a great 52 week severance no matter your years of service. Hope for the best prepare for the worst. Gang gang!
     
  11. anonymous

    anonymous Guest

    Based on past acquisition and mergers it means all the component Abvie representatives will be fired and Forest reps will replace them
     
  12. anonymous

    anonymous Guest

    Forest what, who??? Bye